Emergent BioSolutions | EBS - Sales Revenues


Emergent BioSolutions reported $276.6M in Sales Revenues for its fiscal quarter ending in December of 2023.





Sales Change Date
Acadia Pharmaceuticals USD 268.06M 15.94M Mar/2026
Akebia Therapeutics USD 57.62M 1.14M Dec/2025
ALKERMES USD 392.91M 8.41M Mar/2026
Alnylam Pharmaceuticals USD 1.17B 70M Mar/2026
Amarin USD 49.22M 451K Dec/2025
ANI Pharmaceuticals USD 237.5M 9.56M Mar/2026
BioMarin Pharmaceutical USD 766M 109M Mar/2026
Coherus Biosciences USD 12.75M 1.18M Dec/2025
Emergent BioSolutions USD 276.6M 6.1M Dec/2023
Exelixis USD 610.8M 12.14M Mar/2026
Glaxosmithkline GBP 10.09B 1.37B Mar/2026
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Ionis Pharmaceuticals USD 246M 43M Mar/2026
Ironwood Pharmaceuticals USD 106.51M 58.8M Mar/2026
Lexicon Pharmaceuticals USD 5.49M 8.69M Dec/2025
Lonza CHF 3.58B 63M Jun/2025
Merck USD 16.29B 110M Mar/2026
Moderna USD 389M 289M Mar/2026
Myriad Genetics USD 200.4M 9.4M Mar/2026
Nektar Therapeutics USD 21.81M 2.32M Dec/2025
Neurocrine Biosciences USD 811M 5.5M Mar/2026
Pacira USD 177M 19.87M Mar/2026
Pfizer USD 14.5B 3.08B Mar/2026
PTC Therapeutics USD 273M 108.3M Mar/2026
Sanofi EUR 11.24B 60M Mar/2026
Sarepta Therapeutics USD 730.8M 287.9M Mar/2026
United Therapeutics USD 781.5M 8.7M Mar/2026
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024
Xoma USD 25K 5M Sep/2024